# Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct05854498/  
OnCo record `nct05854498` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of irinotecan (and liposomal irinotecan) and bevacizumab (glioblastoma use) in colorectal cancer, run by University of Wisconsin, Madison, now recruiting.

## Summary

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT05854498 by University of Wisconsin, Madison, with a registry enrolment figure of 50 participants, started 2023-10-13 and due to reach its primary completion in 2028-09. Interventions recorded: Liposomal irinotecan; TAS102; Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression Free Survival (PFS). Colorectal eligibility wording from the registry: "* Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05854498
- Phase: 2
- Setting: Phase II Study of Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
- Sponsor: University of Wisconsin, Madison
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05854498: https://clinicaltrials.gov/study/NCT05854498

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/)
- companies: [Ipsen](https://onco.cc/companies/ipsen/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05854498.json